GP100 target MAR-T cell therapy (Beike)

N/A

Report date: 2025/02/19 11:00:58

Base Information

Drug NameGP100 target MAR-T cell therapy (Beike)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionMelanocyte protein PMEL modulators
TargetsMelanocyte protein PMEL
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShenzhen Beike Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Beike Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A